Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients

Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2022-11, Vol.140 (Supplement 1), p.8658-8659
Hauptverfasser: Jang, Jun Ho, Demichelis, Roberta, Nogaieva, Larysa, Wong, Lily LL, Lim, Soo Min, Kim, Younsoo, Park, Jihye
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 8659
container_issue Supplement 1
container_start_page 8658
container_title Blood
container_volume 140
creator Jang, Jun Ho
Demichelis, Roberta
Nogaieva, Larysa
Wong, Lily LL
Lim, Soo Min
Kim, Younsoo
Park, Jihye
description
doi_str_mv 10.1182/blood-2022-158387
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_158387</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122054507</els_id><sourcerecordid>S0006497122054507</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1377-e9133d9bec20cc4ac5b7c1726046a52bb11a18a2bb467d44fdcfa7c7297c179e3</originalsourceid><addsrcrecordid>eNp9kE1OwzAQhS0EEqVwAHZewiJgOz9OxKqtCo1UQUVhbTmOQwclMbKdinAODkxKWLOakea9mTcfQpeU3FCastuiNqYMGGEsoHEapvwITWjM0oAQRo7RhBCSBFHG6Sk6c-6dEBqFLJ6g761uHXjYg-_xrJV178Bh02K_03hjoZG2x8uqAiVVj5-162o_zCu8nVOGr5aqq-Gra2SB52AcNFBLe403O-k0zvMcb31X9hhavJHWfPaukTV-NMp3driFV7oxb7UpoO0syEHjQbfenaOTStZOX_zVKXq9X74sVsH66SFfzNaBoiHngc5oGJZZoRUjSkVSxQVXlLOERImMWVFQKmkqhyZKeBlFVakqyRVn2UGW6XCK6LhXWeOc1ZX4GD8WlIgDVvGLVRywihHr4LkbPXoItgdthVNDaKVLsFp5URr4x_0DQtSC4Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Jang, Jun Ho ; Demichelis, Roberta ; Nogaieva, Larysa ; Wong, Lily LL ; Lim, Soo Min ; Kim, Younsoo ; Park, Jihye</creator><creatorcontrib>Jang, Jun Ho ; Demichelis, Roberta ; Nogaieva, Larysa ; Wong, Lily LL ; Lim, Soo Min ; Kim, Younsoo ; Park, Jihye</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-158387</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.8658-8659</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Jang, Jun Ho</creatorcontrib><creatorcontrib>Demichelis, Roberta</creatorcontrib><creatorcontrib>Nogaieva, Larysa</creatorcontrib><creatorcontrib>Wong, Lily LL</creatorcontrib><creatorcontrib>Lim, Soo Min</creatorcontrib><creatorcontrib>Kim, Younsoo</creatorcontrib><creatorcontrib>Park, Jihye</creatorcontrib><title>Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kE1OwzAQhS0EEqVwAHZewiJgOz9OxKqtCo1UQUVhbTmOQwclMbKdinAODkxKWLOakea9mTcfQpeU3FCastuiNqYMGGEsoHEapvwITWjM0oAQRo7RhBCSBFHG6Sk6c-6dEBqFLJ6g761uHXjYg-_xrJV178Bh02K_03hjoZG2x8uqAiVVj5-162o_zCu8nVOGr5aqq-Gra2SB52AcNFBLe403O-k0zvMcb31X9hhavJHWfPaukTV-NMp3driFV7oxb7UpoO0syEHjQbfenaOTStZOX_zVKXq9X74sVsH66SFfzNaBoiHngc5oGJZZoRUjSkVSxQVXlLOERImMWVFQKmkqhyZKeBlFVakqyRVn2UGW6XCK6LhXWeOc1ZX4GD8WlIgDVvGLVRywihHr4LkbPXoItgdthVNDaKVLsFp5URr4x_0DQtSC4Q</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Jang, Jun Ho</creator><creator>Demichelis, Roberta</creator><creator>Nogaieva, Larysa</creator><creator>Wong, Lily LL</creator><creator>Lim, Soo Min</creator><creator>Kim, Younsoo</creator><creator>Park, Jihye</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients</title><author>Jang, Jun Ho ; Demichelis, Roberta ; Nogaieva, Larysa ; Wong, Lily LL ; Lim, Soo Min ; Kim, Younsoo ; Park, Jihye</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1377-e9133d9bec20cc4ac5b7c1726046a52bb11a18a2bb467d44fdcfa7c7297c179e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jang, Jun Ho</creatorcontrib><creatorcontrib>Demichelis, Roberta</creatorcontrib><creatorcontrib>Nogaieva, Larysa</creatorcontrib><creatorcontrib>Wong, Lily LL</creatorcontrib><creatorcontrib>Lim, Soo Min</creatorcontrib><creatorcontrib>Kim, Younsoo</creatorcontrib><creatorcontrib>Park, Jihye</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jang, Jun Ho</au><au>Demichelis, Roberta</au><au>Nogaieva, Larysa</au><au>Wong, Lily LL</au><au>Lim, Soo Min</au><au>Kim, Younsoo</au><au>Park, Jihye</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>8658</spage><epage>8659</epage><pages>8658-8659</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-158387</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2022-11, Vol.140 (Supplement 1), p.8658-8659
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2022_158387
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T15%3A46%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sensitivity%20Analysis%20on%20the%20Primary%20Efficacy%20Results%20of%20SB12%20(Eculizumab%20Biosimilar)%20Phase%20III%20Study%20in%20Paroxysmal%20Nocturnal%20Hemoglobinuria%20Patients&rft.jtitle=Blood&rft.au=Jang,%20Jun%20Ho&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=8658&rft.epage=8659&rft.pages=8658-8659&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-158387&rft_dat=%3Celsevier_cross%3ES0006497122054507%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122054507&rfr_iscdi=true